Rebalix
Amundi · sheet of 10 September 2026
Amundi · sheet of 10 September 2026ETF sheet · official issuer and register data
Amundi PEA Nasdaq-100 UCITS ETF S - Acc
PNAS · FR001400ZGR7 · class UCITS ETF S - Acc · EUR · domicile France
Equity · United States · Large capSFDR art. 6
Index tracked: NASDAQ-100 Notional Net Total Return Index
- TER
- 0.30%+ trans. 0.00%
- Fund size
- 19 m EUR
- Tracking difference
- —not computable
- 🇮🇹 tax rate
- —white list not published
- Replication
- Synthetic (swap)
- Income
- Accumulating
Launch 3 Jun 2025 · costs from the KID as of 2 Sept 2026 · 65 securities held · 5 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · unofficial translation, the original prevails · 4 Aug 2026
The fund is a passively managed index-tracking UCITS. The investment objective of the Fund is to replicate, both upward and downward, the evolution of the NASDAQ-100 TM Net Total Return index (net dividends reinvested) (the "Benchmark Index"), denominated in USD and representative of the US technology sector, while minimising the tracking error between the performance of the Fund and that of the Benchmark Index. The anticipated level of tracking error under normal market conditions is indicated in the Fund's prospectus. Nasdaq's website…
Performance since series start (in euro) — base 100
3 Jun 2025 → 8 Sept 2026 · dividends reinvested where declared by the issuer
Returns in euro
| 1 year | +25.9% |
| 3 years | series too young |
| 5 years | series too young |
| 10 years | series too young |
| Since series start | +33.5% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 19.29% | 19.29% | — |
| Max drawdown | −11.13% | −11.13% | — |
| Sharpe | 1.18 | 1.18 | — |
| Sortino | 1.70 | 1.70 | — |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · PNAS · FR001400ZGR71
RebalixPNAS · FR001400ZGR7 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years
Not honestly computable: index series not published by the issuer
Holdings
Synthetic replication: top positions of the substitute basket (swap collateral), not the fund’s exposure · 1 Sept 2026 · 65 securities · top-10 weight = 54.0%
| Top holdings | Weight |
|---|---|
| 8.8% | |
| 8.7% | |
| 6.7% | |
| 5.0% | |
| 5.0% | |
| 4.6% | |
| 4.5% | |
| 4.4% | |
| 3.8% | |
| 2.7% |
Listing venues
ESMA register (FIRDS) and official exchange lists
AE5L · Börse Hamburg, Börse Hannover, Börse Stuttgart, Tradegate Exchange
PNAS · Euronext Paris
+ 9 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/FR001400ZGR7
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/FR001400ZGR7
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · PNAS · FR001400ZGR72